Partial sale of Nomura Research Institute shares
First written in FY2020-Q1. 2 of 3 entries say "Achieved", first in FY2020-Q1. Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3AdvancedAnnual report
「For the nine months ended the third quarter, total other operating revenue after financial expenses was ¥126.9 billion, primarily due to ¥28.0 billion in gains related to the sale of common shares of Nomura Research Institute, Ltd. recognized in December 2022. Expenses other than financial expenses were ¥69.1 billion, and pretax income was ¥57.7 billion.」
A gain of approximately ¥28 billion related to the sale of NRI common shares was recognized in December 2022, disclosing a further completed sale-related transaction following previous partial sales. Details such as the number of shares sold were not provided. - FY2020-Q2AchievedAnnual report
「Following the completion of the tender offer, on 21 August 2019 we transferred to NRI 101,889,300 common shares of NRI held by us for ¥159,966,201,000, at a sale price of ¥1,570 per share.」
The sale of 101,889,300 shares through NRI’s tender offer for its own shares was completed on 21 August 2019, and the sale proceeds of ¥159,966,201,000 were disclosed. - FY2020-Q1AchievedAnnual report
「We tendered 101,910,700 common shares of Nomura Research Institute, Ltd. held by us into NRI’s tender offer for its own shares. The tender offer ended on 29 July 2019, and 101,889,300 of the shares we tendered were purchased.」
The sale of 101,889,300 shares was completed through NRI’s tender offer for its own shares. Pretax profit of approximately ¥73 billion is expected to be recognized in the second quarter of the fiscal year ending March 2020, and NRI is expected to remain an equity-method affiliate.